China SXT Pharmaceuticals, Inc.
SXTC
$2.16
$1.17118.43%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 140.99% | 113.43% | 47.79% | -71.09% | -241.56% |
| Total Depreciation and Amortization | -30.45% | -24.53% | -18.78% | -9.71% | -0.41% |
| Total Amortization of Deferred Charges | -28.89% | -19.43% | -12.75% | -21.80% | -30.68% |
| Total Other Non-Cash Items | -161.31% | -139.83% | -72.59% | 61.93% | 183.93% |
| Change in Net Operating Assets | -197.24% | -162.94% | -126.96% | 46.59% | 323.95% |
| Cash from Operations | -2,333.09% | -2,313.33% | -2,286.14% | -4,027.94% | -454.14% |
| Capital Expenditure | 86.17% | 88.47% | 90.11% | 56.50% | 17.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.81% | -38.70% | -42.81% | -99.45% | -99.80% |
| Cash from Investing | 248.13% | 266.97% | 316.39% | -100.06% | -100.34% |
| Total Debt Issued | 110.68% | 25.23% | -62.86% | -17.30% | 48.17% |
| Total Debt Repaid | -86.31% | -551.95% | -40.62% | 97.25% | 132.98% |
| Issuance of Common Stock | -- | -- | -- | -58.67% | -29.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 58.78% | 66.60% | 74.43% | 40.42% | 9.70% |
| Cash from Financing | -4.97% | -48.36% | -189.22% | 363.98% | 271.60% |
| Foreign Exchange rate Adjustments | 168.50% | 93.22% | 27.10% | 9.36% | -13.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.93% | -82.92% | -394.15% | -32.76% | 187.63% |